A Chance To Own The Venous Space: BTG Acquires Novate
Complications with inferior vena cava (IVC) filters and subsequent patient-injury lawsuits have made this a tricky space for medical technology innovators, but BTG has not been deterred. The UK company has entered the fray with a technology developed by Novate Medical, and as a bioconvertible product BTG believes it has key advantages compared with other offerings.
You may also be interested in...
Boston Scientific's Drive To Add To Core Strength Continues With BTG Buy
When Boston Scientific chief medical officer Ian Meredith spoke in mid-2018 of the group's appetite for core M&A, there was a sense that more strategic moves were likely before the year was out. The inference was right, and a busy year for Boston Scientific got much busier when it made a cash offer for UK interventional medicine specialist BTG PLC. The bid values the target company at $4.28 billion, and completion is expected by mid-2019.
Boston Scientific Agrees To Pay $4.2Bn For UK Interventional Oncology Firm BTG
A busy year of M&A for Boston Scientific just got busier with a $4.2bn cash offer for UK interventional medicine specialist BTG. Completion is expected by mid-year 2019.
BTG Enters IVC Market With $150M Novate Bolt-On
The diversified UK firm is betting $20m upfront and up to $150m total on a novel inferior vena cava filter technology.